News | November 21, 2024
Siegfried opens global R&D Center for Drug Substances in Switzerland
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
Emcure has launched an awareness campaign to help spread the word about male anemia
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Modernization and supply chain diversity drive new growth
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Subscribe To Our Newsletter & Stay Updated
